Skip to search formSkip to main contentSkip to account menu

QVA149

National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

GlycopyrrolateIndansQuinolones
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
QVA149 Significantly Improves Lung Function and Reduces Rescue Medication Use Compared With Its Monocomponents in COPD Patients With Moderate-to-Severe Airflow Limitation: Pooled Analysis From the…
Review
2015
Review
2015
Correction
  • Thorax
  • 2015
  • Corpus ID: 219205010
decisions in the United States. Value Health 2009;12(Suppl 2):S39–44. 29 Mahler DA, Decramer M, D’Urzo A, et al. Dual… 
2015
2015
evaluation Of Efficacy And Safety Of Switching To Qva149 From Salmeterol/fluticasone In Symptomatic Patients With Moderate-to-severe Copd: The Flash Study : abstract Id – 291
2014
2014
Lack of clinically relevant differences between combination therapy and monotherapy in COPD
To the Editor: Bateman et al. [1] reported significantly greater mean improvements with indacaterol/glycopyrronium combination… 
2014
2014
QVA149 bietet bei COPD-Patienten einen schnellen Wirkeintritt, der über die Behandlungsdauer aufrechterhalten wird
2013
2013
QVA149 einmal täglich verbessert signifikant die Lungenfunktion und die Symptome bei COPD Patienten im Vergleich zu Fluticason/Salmeterol zweimal täglich: die ILLUMINATE Studie